Nogo Receptor (extracellular) Blocking Peptide

Overview

Nogo Receptor (extracellular) Blocking Peptide is a Synthetic peptide used in research settings. It is commonly applied as a tool reagent related to RTN4R biology and/or assay development. It is supplied in Lyophilized powder format to support flexible downstream use in RUO workflows. Researchers commonly pair it with applications such as WB, IHC, CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA.

Key elements and design rationale

• Quality attributes: Purity: >70%; Identity/confirmation: Confirmed by amino acid analysis and mass spectrometry; Lot QC: Western blot analysis..
• Immunogen context: (C)GDSPPGNGSGPRHIND corresponding to amino acid residues 366-381 of the human Nogo receptor.
• Antigen preadsorption control: 1 µg peptide per 1 µg antibody.

When used as a biochemical or pharmacological tool, results are best interpreted relative to the experimental system (species, expression level, and assay readout) and with appropriate negative and competition-style controls where relevant. This product is intended for research use only.

Biological background

Protein and peptide reagents are widely used to probe molecular mechanisms, benchmark assay performance, and support reagent validation. Interpretation depends on the assay context (e.g., binding, functional modulation, competition, or detection) and on how closely the reagent’s sequence/structure matches the biological target in the experimental system.

Research relevance and current trends

• Using high-specificity ligands, toxins, and engineered peptides to dissect closely related receptor/channel subtypes and signaling microdomains.
• Pairing labeled (e.g., fluorescent) proteins/peptides with advanced imaging to map surface expression, trafficking, and nanoscale organization.
• Expanding rigor in antibody validation, including competition/preadsorption concepts and orthogonal approaches (genetic, pharmacologic, and biochemical controls).

Common research applications

• WB: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• IHC: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• CBE- Cell-based ELISA: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• FC- Flow cytometry: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• ICC- Immunocytochemistry: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• IE- Indirect ELISA: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• IF- Immunofluorescence: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• IFC- Indirect flow cytometry: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• IHC- Immunohistochemistry: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• IP- Immunoprecipitation: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• LCI- Live cell imaging: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• N- Neutralization: commonly used to compare signal, binding, or functional readouts across conditions without implying a specific protocol.
• Antibody-related use: often referenced as the immunogen for antibody generation ((C)GDSPPGNGSGPRHIND corresponding to amino acid residues 366-381 of the human Nogo receptor), supporting interpretation of epitope-dependent results.
• Specificity control concept: can support antigen preadsorption-style controls (1 µg peptide per 1 µg antibody) as part of an overall validation strategy.

Across these use cases, changes in signal or functional readout are generally interpreted as evidence of differences in target abundance, accessibility, or engagement, but alternative explanations (matrix effects, off-target interactions, or assay artifacts) should be considered.

Notes for experimental interpretation

• Assay context matters: binding assays, functional modulation, and detection workflows can yield different readouts even for the same target system.
• Target complexity: closely related family members, splice variants, and post-translational modifications can influence apparent specificity and potency.
• Matrix and sample effects: buffer composition, detergents, and biological matrices may alter stability or apparent activity; interpret with appropriate controls.
• Control concepts: competition/preadsorption should be considered alongside orthogonal controls (e.g., genetic perturbation, alternative ligands, or independent antibodies).

Can’t Find What You’re Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.